Protagonist Therapeutics, Inc. (PTGX) is a promising investment opportunity with a market cap of $3.6 billion and $615 million in net cash. Their flagship asset, Icotrokinra (Ico), is nearing FDA approval with strong Phase 2/3 data across various indications, positioning PTGX for significant market share in the IL-23 class.

PTGX also has Rusfertide, targeting polycythemia vera, with Phase 3 results offering potential annual cash flow of $100–$200 million plus a $400 million opt-out payment. With a strong balance sheet, diverse pipeline, and multiple catalysts ahead, PTGX presents an attractive risk/reward profile for long-term biotech investors.

In comparison to a previous bullish thesis on Moderna, Inc. (MRNA), PTGX offers unique strengths in underappreciated clinical assets, royalties, and strategic optionality. With a stock price increase of approximately 100% since coverage, PTGX remains an appealing investment opportunity in the biotech sector for those willing to be patient and capitalize on future growth potential.

Read more at Yahoo Finance: Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory